The study of 104 patients showed a statistically significant reduction in the number of brain lesions observed on serial MRI scans of the brain in the Rituxan-treated group compared to placebo.
“Showing a significant benefit at 24 weeks in this small phase II trial supports our hypothesis that selective B-cell targeted therapy may play an important role in the treatment of MS,” said Hal Barron Genentech senior vice president and chief medical officer.
MS is a neurological disability that typically accumulates over time and includes muscle weakness and spasticity, balance and coordination problems, as well as memory impairment and depression. Relapsing-remitting multiple sclerosis is the most common form of MS and accounts for approximately 65 percent of all MS cases.
Rates of overall adverse events and serious adverse events were comparable between the two treatment groups. The companies continue to monitor the long-term safety of Rituxan treatment.